Ogawa M
Aichi Cancer Center, Nagoya, Japan.
Gan To Kagaku Ryoho. 1992 Jun;19(6):769-74.
The frontline chemotherapy for advanced breast cancer has been either CMF or CAF and the combinations can obtain an overall response rate exceeding 50%, including complete responses of 10-15% and median survival times of 12-18 months. Complete responders have survived longer than patients with partial responses or stable diseases. Consequently, high dose chemotherapy with autologous bone marrow transplantation has been investigated in order to obtain more complete responses and ultimately to obtain a cure in patients responding to induction chemotherapy. Seventeen to 30% of patients who became complete responses have maintained continuously complete responders. Taxol and CI941 are promising agents under investigation.
晚期乳腺癌的一线化疗方案一直是CMF或CAF，这些联合方案可使总缓解率超过50%，包括10%-15%的完全缓解率以及12-18个月的中位生存期。完全缓解者的生存期比部分缓解或病情稳定的患者更长。因此，人们对自体骨髓移植的高剂量化疗进行了研究，以期获得更多的完全缓解，并最终治愈对诱导化疗有反应的患者。17%-30%达到完全缓解的患者持续保持完全缓解状态。紫杉醇和CI941是正在研究的有前景的药物。
